Australia's most trusted
source of pharma news
Posted 25 June 2026 AM
Announcing the positive Phase 3 interim analysis for Avecho Biotechnology’s CBD soft-capsule insomnia treatment, CEO Paul Gavin, described the result as a “huge sigh of relief” for both the Melbourne company and Sandoz, which has already licensed the product’s Australian rights.
Ultimately, Avecho and Sandoz hope to achieve two firsts - registering the first pharmaceutical CBD product for insomnia anywhere in the world and the first over-the-counter CBD product in Australia following regulatory changes in 2020.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.